Regulus Therapeutics Inc.
RGLS
Rang în acțiuni
#17336
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preț acțiune
$8.16
Ultima sincronizare: 2025-06-26
Capitalizare de piață
$234.57M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
-88.86%
Țară
US
Tranzacționează Regulus Therapeutics Inc. (RGLS)
Categorie
Healthcare
Raport P/S pentru Regulus Therapeutics Inc. (RGLS)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Regulus Therapeutics Inc., raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Regulus Therapeutics Inc. din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
